Biotechnology company and drug-delivery platform
innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has
developed and out-licenses its pioneering-drug delivery platform
DehydraTECH(TM), which improves the speed, taste and delivery of bioactive
compounds, including nicotine and cannabinoids. A recent article discussing the
company reads, “Furthermore, the DehydraTECH drug delivery platform increases
bio-absorption by up to 10 times and lessens the time of onset, with effects
being felt within 15 to 20 minutes, as compared to 60 to 120 minutes without
the platform. In addition, the technology is patent protected for cannabidiol
(CBD) and all other nonpsychoactive cannabinoids. Patents are also granted for
THC (tetrahydrocannabinol), other psychoactive compounds and NSAIDs
(nonsteroidal, anti-inflammatory drugs), as well as nicotine and other
molecules. . . . Lexaria Bioscience has partnered with one of the world’s
largest tobacco companies to fund the research and development of the
DehydraTECH technology for oral nicotine. Through wholly owned subsidiary
Lexaria Nicotine LLC, Lexaria is working to propel innovation in oral,
reduced-risk nicotine consumer products utilizing DehydraTECH (http://ibn.fm/1JjdR).”
To view the full article, visit http://ibn.fm/khjf5
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its
disruptive delivery technology, which promotes healthier ingestion methods,
lower overall dosing and higher effectiveness of lipophilic active molecules.
Lexaria has multiple patents pending in over 40 countries around the world and
has patents granted in the United States and Australia for utilization of its
DehydraTECH delivery technology. Lexaria’s technology provides increases in
intestinal absorption rates, more rapid delivery to the bloodstream, and
important taste-masking benefits for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. For more information, visit the
company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and more,
these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment